Strattera is a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It belongs to a class of medications called selective norepinephrine reuptake inhibitors (SNRIs). It works by increasing the levels of norepinephrine in the brain, which helps improve focus and impulse control. This medication may be prescribed for other uses; consult your healthcare provider for personalized advice.
Take Strattera exactly as prescribed by your healthcare provider. Your doctor will likely recommend taking it after your meals or at least one hour before bedtime. Do not skip doses or stop taking the medication without consulting your doctor.
To the best of our knowledge, there is no systematic review on the use of atypical antipsychotics in patients with bipolar disorder. The aim of this systematic review was to compare the effect of different atypical antipsychotics in patients with bipolar disorder. We searched the MEDLINE, EMBASE, Cochrane and reference lists of retrieved articles for the studies published until September 2021. We excluded those studies that used antipsychotics only in bipolar patients.
Antipsychotic medications, including atypical antipsychotics, are indicated for the treatment of schizophrenia, bipolar disorder, and major depressive disorder (MDD), with an incidence of 2–10% (see Table 1). Although atypical antipsychotics are not recommended for treatment of bipolar disorder, they can be prescribed to patients with bipolar disorder who have not responded adequately to conventional antipsychotics [see for further information].
One of the first steps in the treatment of bipolar disorder is the introduction of an atypical antipsychotic. The first atypical antipsychotic is the selective serotonin reuptake inhibitor (SSRI) tricyclic antidepressants (TCAs). The main mechanism of action of the SSRI is the blockade of the reuptake of serotonin [see for further information].
In addition to the first SSRI, antipsychotics have been also used to treat MDD [see for further information].
Several studies have investigated the efficacy of antipsychotic medications in the treatment of patients with bipolar disorder [see for further information]. Some of these studies have investigated the use of atypical antipsychotics in bipolar patients, while others have used a placebo-controlled trial. One of the most well-known trials on the efficacy of atypical antipsychotics in patients with bipolar disorder is the atypical antipsychotic group study (ATAS-P). In this trial, all patients had a mean age of 63.5 years, were diagnosed with bipolar disorder, and were treated with a total of 16 (12 with MDD) atypical antipsychotics. Patients were stratified into two groups by their treatment group. In the group treated with the placebo, patients had an average change in their bipolar symptoms of 5.7 (0.6) years (mean 0.5) [range 0.2–9.9 years] (mean change 0.3) compared to 4.6 (0.5) years (0.2) (range 0.1–6.9 years) in the group treated with the atypical antipsychotic. The group treated with the atypical antipsychotic had a mean change in their bipolar symptoms of 5.0 (0.6) years (0.6) [range 0.2–9.9 years] (mean change 1.8) compared to 2.6 (0.6) years (0.5) (range 0.2–6.9 years) in the group treated with the placebo [see Figure 1A–C].
Figure 1. Effect of atypical antipsychotics in patients with bipolar disorder.
Figure 1: Effect of atypical antipsychotics in patients with bipolar disorder.
In the ATAS-P study, all patients had a mean age of 63.5 years, were diagnosed with bipolar disorder, and were treated with a total of 16 (12 with MDD) atypical antipsychotics. The average change in their bipolar symptoms (mean change 0.5) was similar to the average change in their depressive symptoms (mean change 0.2) (mean change 0.3) [range 0.1–6.9 years]. The average change in their depressive symptoms (mean change 0.2) was similar to the average change in their depressive symptoms (mean change 0.3) (mean change 0.2) [range 0.1–6.9 years].
Another study of the effect of atypical antipsychotics in patients with bipolar disorder was performed in this meta-analysis [see Figure 2A–E]. The authors performed a double-blind, placebo-controlled study in which all patients had a mean age of 60.3 years, were diagnosed with bipolar disorder, and were treated with a total of 12 (12 with MDD) atypical antipsychotics. The average change in their bipolar symptoms (mean change 0.9) was similar to the average change in their depressive symptoms (mean change 0.2) (mean change 0.
As part of our comprehensive guide to Atomoxetine, we’re diving into the latest in medication options for treating attention deficit hyperactivity disorder (ADHD). We’ll cover the latest ADHD treatments and share the most important information about their uses, side effects, and how to treat them safely.
is a prescription medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children ages 6-12 years old.
It is primarily used to help improve the ability to pay attention and concentrate in social situations. It is also known by the brand name Strattera.
Strattera was first introduced to the market in 2002. It works by increasing the levels of norepinephrine in the brain, which helps improve attention span, balance attention, and reduce hyperactivity.
Doctors also prescribe it as a mood stabilizer to help with the symptoms of depression and anxiety in adults with ADHD.
Like Strattera, it is also used off-label to treat depression in children and adolescents with ADHD.
It is typically taken once a day, with or without food. However, your doctor may start you on a low dose and gradually increase your dose.
Take it as directed by your doctor, usually once a day, with or without food. The dose can be adjusted based on how you react to the medication. It is important to stick to the prescribed schedule, especially in the case of missed doses, and to be aware of any potential side effects.
An ADHD medication works by balancing certain neurotransmitters in the brain, which are responsible for regulating attention, focus, and impulsivity.
The neurotransmitters norepinephrine and dopamine regulate the activity of the brain cells involved in attention and behavior regulation. These neurotransmitters are particularly important for attention span and attention toggling tasks.
By increasing norepinephrine levels in the brain, Strattera helps to improve attention span, balance attention, and reduce hyperactivity. This medication also reduces impulsivity, the inability to concentrate, and the inability to stay focused for long periods.
As mentioned earlier, side effects of Strattera are generally mild and short-lived.
These include:
If you experience severe side effects or have concerns about them, talk to your doctor.
The most common side effects include:
If these side effects persist or worsen, it is important to contact your doctor immediately.
Before starting Strattera, it is important to be aware of the following precautions and warnings:
Strattera is a medication that has been available in the U. S. since the 1990s. It is a selective norepinephrine reuptake inhibitor (SNRI), and the generic name of atomoxetine is atomoxetine HCl. It works by blocking the reuptake of norepinephrine, a neurotransmitter in the brain that helps regulate mood, emotions, appetite, and other aspects of life.
The FDA approved Strattera in 2002. Strattera is now available as a generic medication.
Strattera was the first norepinephrine reuptake inhibitor (NRI) to become available. It was designed to treat attention deficit hyperactivity disorder (ADHD), narcolepsy, and high blood pressure. Unlike other medications, Strattera is non-stimulant. It works by increasing the levels of norepinephrine in the brain, which can help improve attention, focus, and impulse control.
Strattera is the brand name for atomoxetine HCl. It belongs to a class of drugs called norepinephrine reuptake inhibitors (NIRIs), which work by increasing levels of norepinephrine in the brain. This allows for better focus and control, and may even help with ADHD symptoms.
Strattera is not FDA-approved for use in the United States and Europe. It is not approved for use in the EU. However, it is widely available in pharmacies, including Canada, Mexico, and the United Kingdom. It’s important to note that while Strattera is approved for use in the EU, it is not FDA-approved for use in the United States.
Strattera comes in three different doses: 25, 50, and 100 mg. Each dose will depend on the patient’s condition. The typical starting dose for most patients is 50 mg, but the dose may be adjusted based on response.
The initial dosage for ADHD symptoms is 25 mg, and the dose may be increased based on response. Strattera can be prescribed as a monotherapy or in combination with stimulants like Adderall, Concerta, or Intuniv. Strattera can be prescribed for both primary and secondary prevention. However, Strattera should not be used in the first- or second-line treatment for ADHD, as it can cause weight gain, which can negatively impact daily life.
Strattera can be taken with or without food. However, it is important to follow the prescribed dosing instructions carefully. Strattera should not be taken with grapefruit juice, which can increase the risk of side effects. It is important to take Strattera at the same time each day to maintain consistent levels in your blood. If you have an irregular heart rhythm or are taking other medications that can cause high blood pressure, Strattera may not be effective in treating your ADHD symptoms.
However, it is important to note that Strattera should be taken with caution and at a low dose. Before taking Strattera, always talk to your healthcare provider about your medical history, especially if you have any preexisting medical conditions.
It’s important to understand that Strattera is not a cure for ADHD. It is a treatment that helps to regulate your mood and reduce anxiety. It may also help in the prevention of certain conditions such as bipolar disorder and schizophrenia. Strattera is a medication that can be used to treat other conditions such as anxiety and depression. If you have a history of heart disease or a history of stroke, talk with your doctor before taking Strattera to ensure that it is the right choice for you.
The most common side effects of Strattera are sleepiness, dizziness, drowsiness, dry mouth, nausea, and fatigue. These side effects are usually mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.
Stade de France Pharmacy